Health Care · Biological Products, (No Diagnostic Substances)

CADL Candel Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 184138776 filings
Russell 2000

CADL at a glance

Candel Therapeutics, Inc. (CADL, SEC CIK 1841387) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Candel Therapeutics, Inc. (CADL) shares worth $165.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Tak Paul Peter on September 11, 2026 of 59,379 shares at $10.46 per share.
  • In the last 90 days, CADL insiders reported 0 open-market purchases ($0) and 2 open-market sales ($3.2M) on Form 4, a net sale of $3.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 2 sells
Net −$3.2M
13F holders
24 funds
$165.3M · +0 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added regulatory risk: June 2026 FDA guidance may require additional clinical data despite a single-trial approval pathway
  • Most material financial update: $203.1 million cash expected to fund operations into Q2 2028
  • Debt risk: Trinity facility totals $130.0 million, with $50.0 million outstanding and covenant-triggered acceleration possible
  • Near-term operational risk: Small eligible brain-cancer population may delay linoserpaturev trial enrollment
  • Compliance risk: GDPR violations may trigger fines up to €20 million or 4% of annual global revenues

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales generated
  • Net loss $21.9M vs $11.3M YoY, operating expenses $23.0M vs $13.2M
  • R&D highest spending line: $15.6M vs $8.5M, driven by aglatimagene development
  • Cash and equivalents $203.1M, operating cash use $58.3M, financing cash inflow $142.6M
  • Outlook: cash runway into Q2 2028, additional capital required for NSCLC phase 3 and commercialization preparation

AI summary of the CADL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue-free biotech reported net loss $21.9M, versus $11.3M, with R&D spending rising to $15.6M to advance aglatimagene programs
  • Cash $203.1M, up from $119.7M at year-end, supports operations into Q2 2028 under current plans, reducing near-term financing pressure
Filed Nov 12, 2026Full analysis →

Item 8.01: Other Events

  • New ATM facility authorizes up to $50 million in additional common-stock sales through Jefferies
  • Prior 2025 ATM fully utilized, with approximately $50 million sold as of November 12, 2026
Filed Sep 10, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded from 10 to 11 directors; Martine Zimmermann appointed independent Class III director through 2027 annual meeting
  • Regulatory expertise spanning FDA, EMA and Japanese authorities strengthens oversight of drug-development and approval strategy

Item EX-99.1: Item EX-99.1

  • Martine Zimmermann appointed to Candel’s Board effective September 8, 2026
  • More than 30 years of regulatory and quality experience strengthens oversight ahead of planned BLA submission

Item 7.01: Regulation FD Disclosure

  • Martine Zimmermann, PharmD appointed to Candel Therapeutics’ Board of Directors
  • Board addition may strengthen pharmaceutical development and commercialization expertise

AI summaries of CADL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CADL

Don't miss the next CADL filing

  • Alerts as it files. A push when CADL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CADL, by share count.
  • Ask anything. An AI agent that reads every CADL filing and answers with sources.

CADL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Ostrovsky MariaANov 3, 2026-
Loggia NicolettaASep 30, 2026$8.68
Manning Paul BASep 30, 2026$8.68
PAPA JOSEPH CASep 30, 2026$8.68
Tak Paul PeterSellSep 11, 2026$10.46
Tak Paul PeterMSep 10, 2026$1.55
Tak Paul PeterSellSep 10, 2026$11.50
Tak Paul PeterMSep 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$38.4M-$33.4M-$48.3M
Net Income-$37.9M-$55.2M-$38.2M
Balance Sheet
Total Assets$41.2M$106.9M$125.2M
Equity$12.7M$66.3M$51.9M
ROE-297.7%-83.2%-73.5%
Per Share
EPS$-1.31$-1.74$-0.72
Cash Flow
Operating CF--$27.0M-$38.3M
CapEx$457K$16K$587K

Source: XBRL data in Candel Therapeutics, Inc. (CADL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CADL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CADL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$165.3M
Q2 202624$265.3M
Q1 202623$97.3M
Q4 202518$87.4M
Q3 202519$74.8M
Q2 202519$74.0M
Q1 202518$61.1M
Q4 202410$59.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 155 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CADL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
4Nov 5, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 11, 2026--
8-KSep 10, 2026Analysis-
4Sep 10, 2026--
8-KSep 9, 2026Analysis-
4Aug 19, 2026--
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
SC 13GJul 27, 2026-
4Jul 8, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 24, 2026--

Related Health Care companies

All Health Care →

CADL SEC filings: frequently asked questions

Are CADL insiders buying or selling?

In the last 90 days, Candel Therapeutics, Inc. (CADL) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $3.2 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CADL stock?

As of September 30, 2026, the largest Candel Therapeutics, Inc. (CADL) holders among the 13F filers tracked by SignalX were BlackRock ($54.1 million), State Street Corp ($39.7 million), Vanguard Capital Management LLC ($30.8 million), Millennium Management ($10.1 million), Vanguard Portfolio Management LLC ($5.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did CADL report in its latest 8-K?

Candel Therapeutics, Inc. (CADL) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest CADL SEC filings?

Candel Therapeutics, Inc. (CADL) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 5, 2026.

What is CADL's SEC CIK number?

Candel Therapeutics, Inc. (CADL)'s SEC Central Index Key (CIK) is 1841387. EDGAR lists every CADL filing under that number.

Ask anything about CADL

The research agent reads CADL's filings, financials, insider trades and 13F holders, then answers with sources.